Skip to main content
Log in

Comparison of the radiomics-based predictive models using machine learning and nomogram for epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma

  • Scientific Paper
  • Published:
Physical and Engineering Sciences in Medicine Aims and scope Submit manuscript

Abstract

The purpose of this study is to develop the predictive models for epidermal growth factor receptor (EGFR) mutation status and subtypes [exon 21-point mutation (L858R) and exon 19 deletion mutation (19Del)] and evaluate their clinical usefulness. Total 172 patients with lung adenocarcinoma were retrospectively analyzed. The analysis of variance and the least absolute shrinkage were used for feature selection from plain computed tomography images. Then, radiomic score (rad-score) was calculated for the training and test cohorts. Two machine learning (ML) models with 5-fold were applied to construct the predictive models with rad-score, clinical features, and the combination of rad-score and clinical features. The nomogram was developed using rad-score and clinical features. The prediction performance was evaluated by the area under the receiver operating characteristic curve (AUC). Finally, decision curve analysis (DCA) was performed using the best ML and nomogram models. In the test cohorts, the AUC of the best ML and the nomogram model were 0.73 (95% confidence interval, 0.59–0.87) and 0.79 (0.65–0.92) in the EGFR mutation groups, 0.83 (0.67–0.99) and 0.85 (0.72–0.97) in the L858R mutation groups, as well as 0.77 (0.58–0.97) and 0.77 (0.60–0.95) in the 19Del groups. The DCA showed that the nomogram models have comparable results with ML models. We constructed two predictive models for EGFR mutation status and subtypes. The nomogram models had comparable results to the ML models. Because the superiority of the performance of ML and nomogram models varied depending on the prediction groups, appropriate model selection is necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG et al (2011) Non-small-cell lung cancer. Lancet 378:1727–1740. https://doi.org/10.1016/S0140-6736(10)62101-0

    Article  PubMed  Google Scholar 

  2. Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M et al (2016) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26:32–42. https://doi.org/10.1007/s00330-015-3814-0

    Article  PubMed  Google Scholar 

  3. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817–1824. https://doi.org/10.1111/j.1349-7006.2007.00607.x

    Article  CAS  PubMed  Google Scholar 

  4. Jänne PA, Engelman JA, Johnson BE (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23:3227–3234. https://doi.org/10.1200/JCO.2005.09.985

    Article  CAS  PubMed  Google Scholar 

  5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388. https://doi.org/10.1056/nejmoa0909530

    Article  CAS  PubMed  Google Scholar 

  6. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128. https://doi.org/10.1016/S1470-2045(09)70364-X

    Article  CAS  PubMed  Google Scholar 

  7. Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R et al (2015) Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiother Oncol 115:120–127. https://doi.org/10.1016/j.radonc.2015.02.018

    Article  CAS  PubMed  Google Scholar 

  8. Li S, Luo T, Ding C, Huang Q, Guan Z, Zhang H (2020) Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: combining radiomics with machine learning. Med Phys 47:3458–3466. https://doi.org/10.1002/mp.14238

    Article  CAS  PubMed  Google Scholar 

  9. Soria JC, Mok TS, Cappuzzo F, Jänne PA (2012) EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 38:416–430. https://doi.org/10.1016/j.ctrv.2011.10.003

    Article  CAS  PubMed  Google Scholar 

  10. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R et al (2017) Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J Natl Cancer Inst 109:1–9. https://doi.org/10.1093/jnci/djw279

    Article  CAS  PubMed  Google Scholar 

  11. Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS et al (2017) EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced asian NSCLC patients. J Thorac Oncol 12:529–538. https://doi.org/10.1016/j.jtho.2016.11.2225

    Article  PubMed  Google Scholar 

  12. Liu Q, Sun D, Li N, Kim J, Feng D, Huang G et al (2020) Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features. Transl Lung Cancer Res 9:549–562. https://doi.org/10.21037/tlcr.2020.04.17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhang L, Zhang Y, Chang L, Yang Y, Fang W, Guan Y et al (2019) Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol Cancer 18:1–6. https://doi.org/10.1186/s12943-019-0939-9

    Article  Google Scholar 

  14. Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577. https://doi.org/10.1148/radiol.2015151169

    Article  PubMed  Google Scholar 

  15. Park H, Sholl LM, Hatabu H, Awad MM, Nishino M (2019) Imaging of precision therapy for lung cancer: current state of the art. Radiology 293:15–29. https://doi.org/10.1148/radiol.2019190173

    Article  PubMed  Google Scholar 

  16. Li S, Ding C, Zhang H, Song J, Wu L (2019) Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer. Med Phys 46:4545–4552. https://doi.org/10.1002/mp.13747

    Article  CAS  PubMed  Google Scholar 

  17. Hong D, Xu K, Zhang L, Wan X, Guo Y (2020) Radiomics signature as a predictive factor for EGFR mutations in advanced lung adenocarcinoma. Front Oncol 10:1–8. https://doi.org/10.3389/fonc.2020.00028

    Article  Google Scholar 

  18. Mei D, Luo Y, Wang Y, Gong J (2018) CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses. Cancer Imaging 18:1–9. https://doi.org/10.1186/s40644-018-0184-2

    Article  Google Scholar 

  19. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446. https://doi.org/10.1016/j.ejca.2011.11.036

    Article  PubMed  PubMed Central  Google Scholar 

  20. Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Cavalho S et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:1–9. https://doi.org/10.1038/ncomms5006

    Article  CAS  Google Scholar 

  21. Zhao W, Wu Y, Xu Y, Sun Y, Gao P, Tan M et al (2020) The potential of radiomics nomogram in non-invasively prediction of epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma. Front Oncol 9:1485. https://doi.org/10.3389/fonc.2019.01485

    Article  PubMed  PubMed Central  Google Scholar 

  22. Velazquez ER, Parmar C, Jermoumi M, Mak RH, Van Baardwijk A, Fennessy FM et al (2013) Volumetric CT-based segmentation of NSCLC using 3D-slicer. Sci Rep 3:1–7. https://doi.org/10.1038/srep03529

    Article  Google Scholar 

  23. Van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104–e107. https://doi.org/10.1158/0008-5472.CAN-17-0339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378. https://doi.org/10.2967/jnumed.110.082404

    Article  PubMed  Google Scholar 

  25. Shiinoki T, Fujimoto K, Kawazoe Y, Yuasa Y, Kajima M, Manabe Y et al (2022) Predicting programmed death-ligand 1 expression level in non-small cell lung cancer using a combination of peritumoral and intratumoral radiomic features on computed tomography. Biomed Phys Eng Express 8:25008. https://doi.org/10.1088/2057-1976/ac4d43

    Article  Google Scholar 

  26. Xiong Z, Jiang Y, Tian D, Zhang J, Guo Y, Li G et al (2022) Radiomics for identifying lung adenocarcinomas with predominant lepidic growth manifesting as large pure ground-glass nodules on CT images. PLoS ONE 17:1–15. https://doi.org/10.1371/journal.pone.0269356

    Article  CAS  Google Scholar 

  27. Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z et al (2016) Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology 281:947–957. https://doi.org/10.1148/radiol.2016152234

    Article  PubMed  Google Scholar 

  28. Kuang Y, Li R, Jia P, Ye W, Zhou R, Zhu R et al (2021) MRI-Based Radiomics: Nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5 cm. Abdom Radiol 46:3772–3789. https://doi.org/10.1007/s00261-021-02992-2

    Article  Google Scholar 

  29. Li X, Yin G, Zhang Y, Dai D, Liu J, Chen P et al (2019) Predictive power of a Radiomic signature based on 18F-FDG PET/CT images for EGFR Mutational Status in NSCLC. Front Oncol 9:1–11. https://doi.org/10.3389/fonc.2019.01062

    Article  Google Scholar 

  30. Cho A, Hur J, Moon YW, Hong SR, Suh YJ, Kim YJ et al (2016) Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer 16:1–8. https://doi.org/10.1186/s12885-016-2251-z

    Article  CAS  Google Scholar 

  31. Zhang B, Liu Q, Zhang X, Liu S, Chen W, You J et al (2020) Clinical utility of a Nomogram for Predicting 30-Days poor outcome in hospitalized patients with COVID-19: Multicenter External validation and decision curve analysis. Front Med 7:1–12. https://doi.org/10.3389/fmed.2020.590460

    Article  Google Scholar 

Download references

Acknowledgements

We thank Medical Physics Research Unit in Yamaguchi University (https://ds0n.cc.yamaguchi-u.ac.jp/~medphys/) for providing support to accomplish this study.

Funding

This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant number 20K16789 (KF), 22K07667 (TS), and the Takeda Science Foundation.

Author information

Authors and Affiliations

Authors

Contributions

YK and TS carried out the experiment. YK wrote the manuscript with support from TS, KF, YY. TH and KM supplied available data in terms of this study and discussed. HT supervised this study. All authors discussed the results and contributed to the final manuscript.

Corresponding author

Correspondence to Takehiro Shiinoki.

Ethics declarations

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board of Yamaguchi University, Japan. The ethics certificate number was #2020−148.

Consent to participants.

This study was retrospective study. We applied opt-out method to obtain consent on this study. The opt-out method was approved by the Institutional Review Board of Yamaguchi University.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawazoe, Y., Shiinoki, T., Fujimoto, K. et al. Comparison of the radiomics-based predictive models using machine learning and nomogram for epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma. Phys Eng Sci Med 46, 395–403 (2023). https://doi.org/10.1007/s13246-023-01232-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13246-023-01232-9

Keywords

Navigation